

## Cellnovo announces its 2018 financial calendar

Paris, France, January 16, 2018 – Cellnovo Group (“Cellnovo” or the “Company” – CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today publishes its financial calendar for the year 2018.

Events	Date *
2017 FY sales	Wednesday, January 17, 2018
2017 FY results and 2018 Q1 sales	Thursday, April 12, 2018
Shareholders’ meeting	Thursday, May 24, 2018
2018 H1 sales and results	Thursday, July 26, 2018
2018 Q3 sales	Thursday, October 11, 2018

\* Subject to modification. Press releases are published after market closes.



### About Cellnovo (Euronext: CLNV)

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems.

For more information go to [www.cellnovo.com](http://www.cellnovo.com)

### About the Cellnovo Diabetes Management System

Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with a blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time.

Cellnovo is listed on Euronext,  
Compartment C  
ISIN: FR0012633360 – Ticker:  
CLNV)





The First Connected All-in-one Diabetes Management System

**Cellnovo**

Chief Executive Officer  
Sophie Baratte  
[investors@cellnovo.com](mailto:investors@cellnovo.com)

**NewCap**

Investor Relations  
Tristan Roquet Montégon  
+ 33 1 44 71 00 16  
[cellnovo@newcap.eu](mailto:cellnovo@newcap.eu)

**NewCap**

Media Relations in France  
Nicolas Merigeau  
+ 33 1 44 71 94 98  
[cellnovo@newcap.eu](mailto:cellnovo@newcap.eu)